Harbin Medisan Pharmaceutical Co (SZSE:002900) 5-Year EBITDA Growth Rate : -5.90% (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Harbin Medisan Pharmaceutical Co 5-Year EBITDA Growth Rate?

Harbin Medisan Pharmaceutical Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.08.

During the past 12 months, Harbin Medisan Pharmaceutical Co's average EBITDA Per Share Growth Rate was -27.20% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 22.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -5.90% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -2.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Harbin Medisan Pharmaceutical Co was 22.70% per year. The lowest was -47.50% per year. And the median was -1.00% per year.

Competitive Comparison of Harbin Medisan Pharmaceutical Co's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Harbin Medisan Pharmaceutical Co's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Harbin Medisan Pharmaceutical Co's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Harbin Medisan Pharmaceutical Co's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Harbin Medisan Pharmaceutical Co's 5-Year EBITDA Growth Rate falls into.

Harbin Medisan Pharmaceutical Co 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Harbin Medisan Pharmaceutical Co (SZSE:002900) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Harbin Medisan Pharmaceutical Co 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Harbin Medisan Pharmaceutical Co's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Harbin Medisan Pharmaceutical Co (SZSE:002900) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Medisan Pharmaceutical Co Ltd (SZSE:002900) » Definitions » 5-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

Beijing Road, Limin Development Zone, Heilongjiang Province, Harbin, CHN, 150025

Website

http://www.medisan.com.cn

Harbin Medisan Pharmaceutical Co Ltd is the pharmaceutical manufacturing company. It is engaged in the research, development, manufacturing and sales of chemical preparations. The main products are oxiracetam injection, mirtazapine tablets, valsartan dispersible tablets, injection brain drugs such as protein hydrolysate, glucose injection and sodium chloride injection. The company is also involved in research, development, production and sales of medical devices.

Executives

Fan Qing Ji	Executives
Zhao Qing Fu	Directors, Directors, and Executives
Liang Yan Fei	Directors, executives
Yao Fa Xiang	Executives
Wang Ming Xin	Executives

Harbin Medisan Pharmaceutical Co (SZSE:002900) Headlines

No Headlines